Abstract
Fundamental and clinical evaluations of TA-058, a new semi-synthetic penicillin for injection, was carried out in the field of obstetrics and gynecology. In vitro antibacterial activities of TA-058 was not so characteristic compared with similar penicillins as far as from our results tested with clinical isolates such as E. coli, K. pneutnoniae, P. mirabilis, P. aeruginosa, S. aureus and S faecalis.
Placental transfer of TA-058 was favorable to some extent and umbilical cord serum concentration reached about a half of maternal serum concentration two hours after intravenous injection of 1.0 gram and also was observed transfer to amniotic fluid, whereas transfer to mother's milk was scarce.
In the clinical trial TA-058 was effective in 81.5 % of the patients tested which were Composedof 13 cases of female genital infections and 14 cases of urinary tract infections by 71.4 %. This might be reflected by relatively higher inclusion rate of complicated urinary tract infections compared with female genital infections which was mainly of moderate or mild cases. Furthermore these clinical results were viewed from the species of causative organisms and the type of infections either of single bacterial-or multiple bacterial infections.
No appreciable side effects were observed.
